Shift Bioscience Secures $16M in Seed Funding to Identify Genes for Epigenetic Clock Reversal

Funding:
Shift Bioscience, a British startup, has raised $16 million in seed funding to pursue research on genes that can rewind the epigenetic clock and rejuvenate aging cells.

Objective:
The company aims to identify genes that can reverse the epigenetic clock, a tool used to estimate a person's age by examining chemical markers on their DNA.

Founder's Vision:
Daniel Ives, CEO and founder of Shift Bioscience, has been working on this concept for seven years, driven by his belief in solving aging through genetic research.

Research Focus:
The startup is focused on anti-aging research, specifically targeting the epigenetic clock to potentially develop treatments for aging-related diseases.

Investment:
The $16 million seed funding will be used to further this research, marking a significant investment in the field of anti-aging and genetic research.